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Abstract 
COVID-19 pneumonia signs and symptoms are not specific and it may be similar to other cases of pneumonia caused 
by other microorganisms such as Mycoplasma pneumonia. This study aimed to investigate the prevalence of M. 
pneumonia co-infection among patients with COVID-19 by a systematic review and meta-analysis. 
Two authors performed the search process independently in Scopus, Web of sciences, and PubMed for studies reporting 
COVID-19-associated Mycoplasma pneumonia co-infections published in the English language from December 2019 to 
1st June 2020. The MeSH terms used in the present review were; “COVID-19”, “co-infection”, “secondary infection”, 
“2019 novel coronavirus”, “2019-nCoV”, “COVID-19 virus”, “coronavirus disease 2019 virus”, “Mycoplasma 
pneumoniae”, “M. pneumoniae”, “prevalence”, and “respiratory pathogens”. Data analyzed using Comprehensive Meta-
analysis (CMA) software. Heterogeneity among included studies was checked by I2 statistic and the Q2 test. M. 
pneumonia co-infection was varied between 1 and 40.6% in the included studies. The combined prevalence of M. 
pneumoniae co-infection among patients with COVID-19 was reported by 17% (95% CI: 7.4–34.3).  
Overall, our systematic review and meta-analysis showed a quite high co-infection of M. pneumonia in patients with 
COVID-19 infection, therefore, routine diagnostic tests are recommended for respiratory pathogens like M. pneumonia, 
because on-time treatment has a beneficial effect on patient survival. Also, an increasing number of cases of 
asymptomatic COVID-19 infection, the differentiation and diagnosis of pneumonia caused by COVID-19 from non-
COVID-19 pneumonia be considered. It helps avoid unnecessary quarantine and waste of medical resources. 
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Introduction 
As we know since December 2019, the infection 
caused by 2019 novel coronavirus (COVID‐19) was 
detected for the first time in Wuhan, Hubei 
Province, China (1). According to pieces of 
evidence, the source of the virus is probably bats, 
which have been transmitted to humans through 
unidentified intermediate animals (2). The route of 
transmission is infected respiratory droplets and 
contact, and the incubation period of which is 
estimated to be between 2 and 14 days (3).  Overall, 
infection occurs by inhaling infected infectious 
particles or by contact with virus-infected surfaces 
and then touching the eyes, nose, and mouth (2). So 
far, several cases of people with the disease and the 
resulting mortalities are being reported every day 
around the world, which is on the rise (2). 
According to reports, the highest incidence of 
morbidity and mortality is seen in elderly people 
with underlying diseases (4). To our knowledge, the 
infection can transmit from asymptomatic people 
and also before the starting of early symptoms (3). 
It is noteworthy that while the number of new cases 
in China has gradually decreased, they have 
increased exponentially in other countries of the 
world (5). Some studies reported the co-infection 
with respiratory pathogens in clinical settings (6, 7). 
One of these opportunistic bacteria that can infect 
the respiratory tract is Mycoplasma pneumoniae. 
Mycoplasma pneumoniae is a type of “atypical” 
microorganisms that generally causes mild 
infections of the respiratory tracts. Actually, 
pneumonia caused by M. pneumoniae is 
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alternatingly denoted as “walking pneumonia” 
because symptoms are milder than pneumonia 
caused by other bacteria (8). Although it is 
important to identify SARS-CoV-2 infection and 
causes the clinicians to take proper infection control 
measures and treatment, they should not forget 
SARS-CoV-2 co-infection (9). Thus, this study 
aimed to investigate the prevalence of M. 
pneumonia co-infection among patients with 
COVID-19 within a systematic review and meta-
analysis. 
Methods 
Search strategy  
Two authors performed the search process 
independently in Scopus, Web of sciences, and 
PubMed for studies reporting COVID-19-associated 
mycoplasma pneumonia co-infections published in 
English language from December 2019 to 1th June 
2020.  
The MeSH terms used in the present review were; 
“COVID-19”, “coinfection”, “secondary infection”, 
“2019 novel coronavirus”, “2019-nCoV”, “COVID-
19 virus”, “coronavirus disease 2019 virus”, 
“Mycoplasma pneumoniae”, “M. pneumoniae”, 





And cohort studies included in the present review 
that met the following eligibility criteria: Cross-
sectional and cohort studies in English language 
that were conducted on reporting COVID-19-
associated mycoplasma pneumonia co-infections 
were considered. Also, studies used the standard 
molecular and phenotypic methods for the detection 
of COVID-19 and M. pneumonia were included.  
Exclusion criteria  
Studies with no address this subject, abstracts, case 
series, case reports, letters to editor, editorials, 
article with missed data, articles reported in 
languages other than English, and all kinds of 
literature reviews were excluded.  
Quality assessment 
Here it was used Briggs Institute (JBI) critical 
appraisal checklist for quality assessment. Based 
on, 10 questions were designed with “yes” and “no” 
answers. Finally, studies were categorized into three 
groups; high (>5 scores), intermediate (4–5 scores), 
and low quality (<4 scores) (10). 
Data extraction 
As presented in Table 1, to authors extracted the 
following data; from each eligible study; first 
author, publication year, location (country), sample 
size, patients’ age, gender (men, and women), 
coinfection (prevalence of M. pneumonia), methods 
used for the detection of COVID-19. 
 
Table 1. Characteristics of included studies 
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Meta-analysis 
Comprehensive Meta-Analysis (CMA) software 
(Biostat, Englewood, NJ) was used for data 
analysis. The results were presented as percentage 
and 95% confidence intervals (95% CIs). 
Heterogeneity among included studies was checked 
by I2 statistic and the Q2 test. Regarding 
heterogeneity between studies, the random-effects 
model was applied. Funnel plot and Egger 
regression test were used to assess publication bias 
among studies included. 
Results 
Study selection  
Overall, 6 out of 198 studies searched through 
electronic databases met the eligibility criteria for 
inclusion as shown in Figure 1.  
 
 
Figure 1. Flow chart of inclusion process 
 
Characteristics of included studies 
According to Table 1, most studies were from 
China (n = 4), Spain (n = 1), and USA (n = 1). 
Patients aged between 16 days and 84 years. All 
studies used of RT-PCR technique for the detection 




M. pneumonia coinfection was varied between 1% 
and 40.6% in included studies. Figure 2 shows the 
combined prevalence of M. pneumoniae coinfection 
among patients with COVID-19 was reported by 
17% (95% CI: 7.4–34.3), Q = 28.9 and Z = 3.3, I2 
=82.7, and t= 3.3. 
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Figure 2. Forest plot of the meta-analysis of the prevalence of M. plasma coinfection among patients with 
COVID-19. 
 
Sources of heterogeneity 
Funnel plot shows the publication bias among the 
included studies (Figure 3). Also, Egger's linear 
regression test was used to further reveal 
publication bias. Findings of Egger's linear 
regression test revealed publication bias, too 
(p = 0.028).  
 
 
Figure 3. Funnel plot of the meta-analysis of the 




Our study showed that M. pneumonia co-infection 
was varied between 1% and 40.6% in included 
studies. Overall, the combined prevalence of M. 
pneumoniae co-infection among patients with 
COVID-19 was reported by 17%. M. pneumoniae is 
among the commonest causes of community-
acquired pneumonia (CAP), predominantly in 
young adults (11). M. pneumoniae is responsible for 
7–20% of CAP (12, 13). Typical CT imaging 
characteristics of COVID-19 pneumonia have been 
discussed by several studies (14, 15), nevertheless, 
their signs and symptoms are not specific and it 
may be similar to other cases of pneumonia caused 
by other microorganisms such as M. pneumonia 
(16, 17). Considerations on the impact of 
respiratory pathogens co-infection on COVID-19 
infection are controversial. One of the studies 
included in this review despite the report of co-
infection in their study cannot conclude that co-
infection can make people more susceptible to 
COVID-19 infection (18). In line with this study, 
others didn’t confirm whether this subject would 
impact the outcome of SARS and MERS due to 
restricted data (19, 20). Another study found that 
co-infection with respiratory pathogens such as 
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Mycoplasma pneumoniae would exacerbate 
COVID-19 infection if the infection was not 
diagnosed and treated. Eventually, it leads to more 
patients staying in the ICU unit (21). Assuming that 
co-infection with other respiratory microorganisms 
does not impact on COVID-19 infection, an 
increasing number of cases of asymptomatic 
COVID-19 infection, the differentiation and 
diagnosis of pneumonia caused by COVID-19 from 
non-COVID-19 pneumonia be considered. It helps 
avoid unnecessary quarantine and waste of medical 
resources (22). A chest CT scan alongside with RT-
PCR technique can be used to quickly and early 
identification of COVID-19 pneumonia (22). The 
most important limitation of this review is that it 
has been done with a small number of studies and 
studies in a short period from three countries: The 
United States, Spain, and especially China.  
Conclusion 
Overall, our systematic review and meta-analysis 
showed a quite high co-infection of M. pneumonia 
in patients with COVID-19 infection, therefore, 
routine diagnostic tests are recommended for 
respiratory pathogens like M. pneumonia, because 
on-time treatment has a beneficial effect on patient 
survival. Also, an increasing number of cases of 
asymptomatic COVID-19 infection, the 
differentiation and diagnosis of pneumonia caused 
by COVID-19 from non-COVID-19 pneumonia be 
considered. It helps avoid unnecessary quarantine 
and waste of medical resources.  
Conflict of Interest 
The author declared that they have no conflict of 
interest. 
Acknowledgment 
Not to declare. 
Funding/Support 
The author declared that there is no financial 




1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et 
al. A novel coronavirus from patients with pneumonia in 
China, 2019. New England Journal of Medicine. 2020. 
2. Singhal T. A review of coronavirus disease-2019 
(COVID-19). The Indian Journal of Pediatrics. 2020:1-6. 
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. 
Clinical features of patients infected with 2019 novel 
coronavirus in Wuhan, China. The lancet. 
2020;395(10223):497-506. 
4. Wu Z, McGoogan JM. Characteristics of and 
important lessons from the coronavirus disease 2019 
(COVID-19) outbreak in China: summary of a report of 
72 314 cases from the Chinese Center for Disease 
Control and Prevention. Jama. 2020;323(13):1239-42. 
5. Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. 
Similarity in case fatality rates (CFR) of COVID-
19/SARS-COV-2 in Italy and China. The Journal of 
Infection in Developing Countries. 2020;14(02):125-8. 
6. Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, et al. 
Early Release-Co-infection with SARS-CoV-2 and 
Influenza A Virus in Patient with Pneumonia, China. 
2020. 
7. Lin D, Liu L, Zhang M, Hu Y, Yang Q, Guo J, et al. 
Co-infections of SARS-CoV-2 with multiple common 
respiratory pathogens in infected patients. Science China 
Life Sciences. 2020:1-4. 
8. Li W, Liu Y, Zhao Y, Tao R, Li Y, Shang S. Rapid 
diagnosis of Mycoplasma pneumoniae in children with 
pneumonia by an immuno-chromatographic antigen 
assay. Scientific reports. 2015;5:15539. 
9. Lai C-C, Wang C-Y, Hsueh P-R. Co-infections among 
patients with COVID-19: the need for combination 
therapy with non-anti-SARS-CoV-2 agents? Journal of 
Microbiology, Immunology and Infection. 2020. 
10. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. 
Methodological guidance for systematic reviews of 
observational epidemiological studies reporting 
prevalence and cumulative incidence data. International 
journal of evidence-based healthcare. 2015;13(3):147-53. 
11. Hammerschlag MR. Mycoplasma pneumoniae 
infections. Current opinion in infectious diseases. 
2001;14(2):181-6. 
12. Pereyre S, Touati A, Petitjean‐Lecherbonnier J, 
Charron A, Vabret A, Bébéar C. The increased incidence 
of M ycoplasma pneumoniae in F rance in 2011 was 
polyclonal, mainly involving M. pneumoniae type 1 
strains. Clinical Microbiology and Infection. 
2013;19(4):E212-E7. 
13. Nir-Paz R, Abutbul A, Moses A, Block C, Hidalgo-
Grass C. Ongoing epidemic of Mycoplasma pneumoniae 
Prevalence of Mycoplasma pneumonia Coinfection among Patients with COVID-19                                    Akbari H. 
Archives of Medical Laboratory Sciences; Volume 6, 2020 (Continuous Volume)  6 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License 
infection in Jerusalem, Israel, 2010 to 2012. 
Eurosurveillance. 2012;17(8):20095. 
14. Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. 
Emerging 2019 novel coronavirus (2019-nCoV) 
pneumonia. Radiology. 2020;295(1):210-7. 
15. Michael C, Adam B, Xueyan M, Ning Z, Mingqian 
H, Xianjun Z, et al. Fayad Zahi A. Jacobi Adam, Li 
Kunwei, Li Shaolin, Shan Hong CT Imaging Features of. 
2019:202-7. 
16. Koo HJ, Lim S, Choe J, Choi S-H, Sung H, Do K-H. 
Radiographic and CT features of viral pneumonia. 
Radiographics. 2018;38(3):719-39. 
17. Franquet T. Imaging of pulmonary viral pneumonia. 
Radiology. 2011;260(1):18-39. 
18. Xing Q, Li G-j, Xing Y-h, Chen T, Li W-j, Ni W, et 
al. Precautions are needed for Patients with COVID-19 
with co-infection of common respiratory pathogens. 
2020. 
19. Kuiken T, Fouchier R, Schutten M, Rimmelzwaan G, 
van Amerongen G, van Riel D, et al. van der WS, 
Escriou N, Manuguerra JC, Stohr K, Peiris JS, Osterhaus 
AD: Newly discovered coronavirus as the primary cause 
of severe acute respiratory syndrome. Lancet. 
2003;362:263-70. 
20. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose 
D, Green K, et al. Identification of severe acute 
respiratory syndrome in Canada. New England Journal of 
Medicine. 2003;348(20):1995-2005. 
21. Fan BE, Lim KGE, Chong VCL, Chan SSW, Ong 
KH, Kuperan P. COVID‐19 and mycoplasma 
pneumoniae co-infection. American journal of 
hematology. 2020. 
22. Liu H, Li W, Zhang L, Liu B, Qi C, Fan W, et al. 
Clinical and CT manifestations of coronavirus disease 
2019 (COVID-19): comparison of suspected cases of 
COVID-19 in isolation and non-COVID-19 pneumonia 
in a single-center study conducted in Beijing, China. 
23. Blasco ML, Buesa J, Colomina J, Forner MJ, Galindo 
MJ, Navarro J, et al. Co‐detection of respiratory 
pathogens in patients hospitalized with Coronavirus viral 
disease‐2019 pneumonia. Journal of Medical Virology. 
2020. 
24. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. 
Clinical characteristics of 138 hospitalized patients with 
2019 novel coronavirus–infected pneumonia in Wuhan, 
China. Jama. 2020;323(11):1061-9. 
25. Richardson S, Hirsch JS, Narasimhan M, Crawford 
JM, McGinn T, Davidson KW, et al. Presenting 
characteristics, comorbidities, and outcomes among 5700 
patients hospitalized with COVID-19 in the New York 
City area. Jama. 2020. 
26. Li H, Chen K, Liu M, Xu H, Xu Q. The profile of 
peripheral blood lymphocyte subsets and serum cytokines 
in children with 2019 novel coronavirus pneumonia. 
Journal of Infection. 2020. 
.  
 
